Definity is a drug owned by Lantheus Medical Imaging Inc. It is protected by 14 US drug patents filed from 2013 to 2024. Out of these, 8 drug patents are active and 6 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be May 04, 2037. Details of Definity's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10588988 | Methods and devices for preparation of ultrasound contrast agents |
May, 2037
(12 years from now) | Active |
| US11529431 | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | Active |
| US9789210 | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | Active |
| US10583208 | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | Active |
| US11857646 | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | Active |
| US11925695 | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | Active |
| US11266750 | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | Active |
| US10583207 | Lipid-encapsulated gas microsphere compositions and related methods |
Dec, 2035
(11 years from now) | Active |
| US8658205 | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
Jun, 2019
(5 years ago) |
Expired
|
| US8685441 | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
Jan, 2019
(5 years ago) |
Expired
|
| US9545457 | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
Jan, 2019
(5 years ago) |
Expired
|
| US6033645 | Methods for diagnostic imaging by regulating the administration rate of a contrast agent |
Jun, 2016
(8 years ago) |
Expired
|
| US5527521 | Low density microspheres and suspensions and their use as contrast agents for computed tomography and in other applications |
Feb, 2015
(9 years ago) |
Expired
|
| US5585112 | Method of preparing gas and gaseous precursor-filled microspheres |
Dec, 2013
(11 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Definity's patents.
Latest Legal Activities on Definity's Patents
Given below is the list of recent legal activities going on the following patents of Definity.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent eGrant | 12 Mar, 2024 | US11925695 |
| Patent eGrant Notification | 12 Mar, 2024 | US11925695 |
| Patent Issue Date Used in PTA Calculation Critical | 12 Mar, 2024 | US11925695 |
| Recordation of Patent Grant Mailed Critical | 12 Mar, 2024 | US11925695 |
| Email Notification Critical | 12 Mar, 2024 | US11925695 |
| Mail Patent eGrant Notification | 12 Mar, 2024 | US11925695 |
| Email Notification Critical | 22 Feb, 2024 | US11925695 |
| Issue Notification Mailed Critical | 21 Feb, 2024 | US11925695 |
| Application Is Considered Ready for Issue Critical | 08 Feb, 2024 | US11925695 |
| Email Notification Critical | 08 Feb, 2024 | US11925695 |
US patents provide insights into the exclusivity only within the United States, but Definity is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Definity's family patents as well as insights into ongoing legal events on those patents.
Definity's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Definity's generic launch date based on the expiry of its last outstanding patent is estimated to be May 04, 2037 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Definity Generics:
There are no approved generic versions for Definity as of now.
Alternative Brands for Definity
Definity which is used for medical imaging using ultrasound technology., has several other brand drugs in the same treatment category and using the same active ingredient (Perflutren). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Lantheus Medcl |
| |||
About Definity
Definity is a drug owned by Lantheus Medical Imaging Inc. It is used for medical imaging using ultrasound technology. Definity uses Perflutren as an active ingredient. Definity was launched by Lantheus Medcl in 2001.
Approval Date:
Definity was approved by FDA for market use on 31 July, 2001.
Active Ingredient:
Definity uses Perflutren as the active ingredient. Check out other Drugs and Companies using Perflutren ingredient
Treatment:
Definity is used for medical imaging using ultrasound technology.
Dosage:
Definity is available in injectable form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 13.04MG/2ML (6.52MG/ML) | INJECTABLE | Prescription | INTRAVENOUS |